KORU Medical Systems, Inc.KRMD
Price (close)
$3.27
Market cap
$151.0M
P/E
—
Revenue (TTM)
$45.1M
Net income
-$1.8M
Dividend yield
—
1-year total return
-16.6%
Net margin
-4.0%
Revenue growth
22.4%
Debt / equity
—
What KORU Medical Systems, Inc. does.
large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United States Food
and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management.
Our focus is primarily concentrated on our mechanical infusion products, the FREEDOM Infusion Systems (which we refer to as the “FREEDOM
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $24.2M | $23.5M | $27.9M | $28.5M | $33.6M | $41.1M |
| Net income | -$1.2M | -$4.6M | -$8.7M | -$13.7M | -$6.1M | -$2.6M |
| Free cash flow | -$1.7M | -$4.7M | -$8.2M | -$5.7M | -$1.6M | -$470,112 |
More on KRMD.
- KORU Medical Systems, Inc. summary
- KORU Medical Systems, Inc. financial statements
- KORU Medical Systems, Inc. key metrics
- KORU Medical Systems, Inc. health scores and style box
- KORU Medical Systems, Inc. earnings
- KORU Medical Systems, Inc. dividends
- KORU Medical Systems, Inc. valuation
- KORU Medical Systems, Inc. ownership and insiders
- KORU Medical Systems, Inc. peers
Figures from KORU Medical Systems, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.